Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22800180 | 0.94 | KDM4E (0.44) | ALDH1A1L3MBTL1KDM4ENPC1RAB9A | |
| SCHEMBL22800876 | 0.87 | KDM4E (0.45) | ALDH1A1L3MBTL1KDM4EMEN1KMT2A | |
| SCHEMBL22800179 | 0.81 | KDM4E (0.43) | ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL22800285 | 0.76 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1KDM4EPTPN11MEN1 | |
| SCHEMBL22799652 | 0.72 | KDM4E (0.44) | KDM4ENPC1RAB9APTPN11MAPK8 | |
| SCHEMBL22800172 | 0.72 | KDM4E (0.63) | ALDH1A1L3MBTL1KDM4ENPC1RAB9A | |
| SCHEMBL20745442 | 0.70 | RAB9A (0.43) | ALDH1A1KDM4ENPC1RAB9AFOLH1 | |
| SCHEMBL465563 | 0.69 | KDM4E (0.55) | ALDH1A1L3MBTL1KDM4ENPC1RAB9A | |
| SCHEMBL22800874 | 0.69 | ALDH1A1 (0.38) | ALDH1A1L3MBTL1 | |
| SCHEMBL22799642 | 0.68 | KDM4E (0.61) | ALDH1A1L3MBTL1KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | Knobbe, Martens, Olson & Bear, LLP | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN2, CAPN1 | ALDH1A1 3918/4885L3MBTL1 3891/4885KDM4E 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.